MedPath

Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Interventions
Radiation: Prophylactic Cranial Irradiation
Radiation: Radiation Therapy
Registration Number
NCT01055197
Lead Sponsor
Radiation Therapy Oncology Group
Brief Summary

RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. This may be an effective treatment for extensive stage small cell lung cancer.

PURPOSE: This randomized phase II trial is comparing how well radiation therapy to the brain works when given with or without radiation therapy to other areas of the body in treating patients with extensive stage small cell lung cancer.

Detailed Description

OBJECTIVES:

Primary

* To compare the 1-year overall median survival rate in patients with extensive stage small cell lung cancer treated with prophylactic cranial irradiation with vs without consolidative extracranial radiotherapy following platinum-based chemotherapy.

Secondary

* To compare treatment-related adverse events in these patients.

* To evaluate patterns of failure in these patients.

* To compare the time to first failure in these patients.

* To evaluate the percentage of the planned radiotherapy dose given to each site.

OUTLINE: This is a multicenter study. Patients are stratified according to response to prior treatment (complete response vs partial response) and number of metastatic lesions (1 vs 2-3). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo prophylactic cranial irradiation 5 days per week for 2 weeks.

* Arm II: Patients undergo prophylactic cranial irradiation as in arm I. Patients also undergo consolidative extracranial radiotherapy to locoregional and residual metastatic disease 5 days per week for 2-3 weeks.

After completion of study treatment, patients are followed up at 2 weeks; at 1, 2, 6, 9, and 12 months; every 6 months for 2 years; and then annually thereafter.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
97
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PCIProphylactic Cranial IrradiationProphylactic Cranial Irradiation (PCI)
PCI + Consolidation RTProphylactic Cranial IrradiationProphylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
PCI + Consolidation RTRadiation TherapyProphylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
Primary Outcome Measures
NameTimeMethod
Overall Survival (12-month Rate Reported)From randomization to last follow-up. Analysis occurred after all patients had been potentially followed for at least 12 months. Maximum follow-up at time of analysis was 46.0 months.

Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. This analysis was planned to occur when all patients had been potentially followed for at least 12 months. The 12-month rate is reported.

Secondary Outcome Measures
NameTimeMethod
Percentage of Patients Experiencing a Grade 3 or Higher Adverse EventFrom randomization to last follow-up. Analysis occurred after all patients had been potentially followed for at least 12 months. Maximum follow-up at time of analysis was 46.0 months.

Adverse events (AE) are graded using CTCAE v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.

Patterns of Failure - Number of Patients With Failure by SiteFrom randomization to last follow-up. Analysis occurred after all patients had been potentially followed for at least 12 months. Maximum follow-up at time of analysis was 46.0 months.

Failure was defined as progressive disease in areas treated with radiation development of measurable disease at sites that had achieved a complete response either with chemotherapy prior to study entry or following radiation, or development of new disease characteristic of small-cell lung cancer dissemination as determined by imaging \[per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\] and physical examination. A patient could be counted in more than one category.

First Failure (12-month Rate Reported)From randomization to last follow-up. Analysis occurred after all patients had been potentially followed for at least 12 months. Maximum follow-up at time of analysis was 46.0 months.

Failure was defined as progressive disease in areas treated with radiation development of measurable disease at sites that had achieved a complete response either with chemotherapy prior to study entry or following radiation, or development of new disease characteristic of small-cell lung cancer dissemination as determined by imaging \[per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\] and physical examination. Time to first failure is defined as time from randomization to the date of first failure, last known follow-up (censored), or death (competing risk). First failure rates are estimated using the cumulative incidence method.

Percentage of Planned Radiotherapy Dose (All Sites) That Was DeliveredFrom start to end of radiation therapy; up to 32 days for Prophylactic Cranial Irradiation arm, up to 68 days for Prophylactic Cranial Irradiation + Consolidation Radiotherapy arm.

Total dose to the brain was to be 25 Gy for all patients. For patients on PCI+consolidative RT, patients were to get 45 Gy at 3 Gy per fraction to the locoregional area as well as to residual metastatic disease. Alternatively, these regions could have received 30-40 Gy in 10 fractions. The total planned dose was determined, and a percentage was calculated based for each patient as total delivered dose / total planned dose.

Trial Locations

Locations (115)

George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus

🇺🇸

New Britain, Connecticut, United States

Case Comprehensive Cancer Center

🇺🇸

Cleveland, Ohio, United States

Integrated Community Oncology Network at Southside Cancer Center

🇺🇸

Jacksonville, Florida, United States

Penrose Cancer Center at Penrose Hospital

🇺🇸

Colorado Springs, Colorado, United States

Saint Agnes Cancer Center at Saint Agnes Medical Center

🇺🇸

Fresno, California, United States

Integrated Community Oncology Network - Orange Park

🇺🇸

Orange Park, Florida, United States

Integrated Community Oncology Network

🇺🇸

Jacksonville Beach, Florida, United States

Georgia Cancer Center for Excellence at Grady Memorial Hospital

🇺🇸

Atlanta, Georgia, United States

Poudre Valley Radiation Oncology

🇺🇸

Fort Collins, Colorado, United States

Flagler Cancer Center

🇺🇸

Saint Augustine, Florida, United States

Emory Crawford Long Hospital

🇺🇸

Atlanta, Georgia, United States

Tel-Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

Memorial Hermann Hospital - Memorial City

🇺🇸

Houston, Texas, United States

Baptist Cancer Institute - Jacksonville

🇺🇸

Jacksonville, Florida, United States

Baptist Medical Center South

🇺🇸

Jacksonville, Florida, United States

Florida Cancer Center - Palatka

🇺🇸

Palatka, Florida, United States

Winship Cancer Institute of Emory University

🇺🇸

Atlanta, Georgia, United States

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

🇺🇸

Chicago, Illinois, United States

Cancer Institute at St. John's Hospital

🇺🇸

Springfield, Illinois, United States

Saint John's Cancer Center at Saint John's Medical Center

🇺🇸

Anderson, Indiana, United States

Radiation Oncology Associates Southwest

🇺🇸

Fort Wayne, Indiana, United States

Parkview Regional Cancer Center at Parkview Health

🇺🇸

Fort Wayne, Indiana, United States

Center for Cancer Care at Goshen General Hospital

🇺🇸

Goshen, Indiana, United States

Community Regional Cancer Care at Community Hospital East

🇺🇸

Indianapolis, Indiana, United States

Community Regional Cancer Care at Community Hospital North

🇺🇸

Indianapolis, Indiana, United States

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

Kansas City Cancer Centers - Southwest

🇺🇸

Overland Park, Kansas, United States

St. Agnes Hospital Cancer Center

🇺🇸

Baltimore, Maryland, United States

Hickman Cancer Center at Bixby Medical Center

🇺🇸

Adrian, Michigan, United States

Henry Ford Macomb Hospital

🇺🇸

Clinton Township, Michigan, United States

Josephine Ford Cancer Center at Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Genesys Hurley Cancer Institute

🇺🇸

Flint, Michigan, United States

Butterworth Hospital at Spectrum Health

🇺🇸

Grand Rapids, Michigan, United States

Lacks Cancer Center at Saint Mary's Health Care

🇺🇸

Grand Rapids, Michigan, United States

Van Elslander Cancer Center at St. John Hospital and Medical Center

🇺🇸

Grosse Pointe Woods, Michigan, United States

West Michigan Cancer Center

🇺🇸

Kalamazoo, Michigan, United States

Mercy Regional Cancer Center at Mercy Hospital

🇺🇸

Port Huron, Michigan, United States

Seton Cancer Institute at Saint Mary's - Saginaw

🇺🇸

Saginaw, Michigan, United States

St. John Macomb Hospital

🇺🇸

Warren, Michigan, United States

University of Mississippi Cancer Clinic

🇺🇸

Jackson, Mississippi, United States

Cancer Institute of Cape Girardeau, LLC

🇺🇸

Cape Girardeau, Missouri, United States

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

🇺🇸

Saint Louis, Missouri, United States

Barnes-Jewish West County Hospital

🇺🇸

Saint Louis, Missouri, United States

Cancer Institute of New Jersey at Cooper - Voorhees

🇺🇸

Voorhees, New Jersey, United States

University of New Mexico Cancer Center

🇺🇸

Albuquerque, New Mexico, United States

New York Oncology Hematology, PC at Albany Regional Cancer Care

🇺🇸

Albany, New York, United States

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center

🇺🇸

New York, New York, United States

NYU Cancer Institute at New York University Medical Center

🇺🇸

New York, New York, United States

Highland Hospital of Rochester

🇺🇸

Rochester, New York, United States

James P. Wilmot Cancer Center at University of Rochester Medical Center

🇺🇸

Rochester, New York, United States

Trinity CancerCare Center

🇺🇸

Minot, North Dakota, United States

McDowell Cancer Center at Akron General Medical Center

🇺🇸

Akron, Ohio, United States

Summa Center for Cancer Care at Akron City Hospital

🇺🇸

Akron, Ohio, United States

Barberton Citizens Hospital

🇺🇸

Barberton, Ohio, United States

Charles M. Barrett Cancer Center at University Hospital

🇺🇸

Cincinnati, Ohio, United States

Cleveland Clinic Cancer Center at Fairview Hospital

🇺🇸

Cleveland, Ohio, United States

Cleveland Clinic Taussig Cancer Center

🇺🇸

Cleveland, Ohio, United States

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

🇺🇸

Columbus, Ohio, United States

Lake/University Ireland Cancer Center

🇺🇸

Mentor, Ohio, United States

Hillcrest Cancer Center at Hillcrest Hospital

🇺🇸

Mayfield Heights, Ohio, United States

UHHS Chagrin Highlands Medical Center

🇺🇸

Orange Village, Ohio, United States

St. Charles Mercy Hospital

🇺🇸

Oregon, Ohio, United States

Parma Community General Hospital

🇺🇸

Parma, Ohio, United States

Flower Hospital Cancer Center

🇺🇸

Sylvania, Ohio, United States

St. Anne Mercy Hospital

🇺🇸

Toledo, Ohio, United States

UHHS Westlake Medical Center

🇺🇸

Westlake, Ohio, United States

Cleveland Clinic - Wooster

🇺🇸

Wooster, Ohio, United States

Natalie Warren Bryant Cancer Center at St. Francis Hospital

🇺🇸

Tulsa, Oklahoma, United States

Three Rivers Community Hospital

🇺🇸

Grants Pass, Oregon, United States

Dubs Cancer Center at Rogue Valley Medical Center

🇺🇸

Medford, Oregon, United States

Northeast Radiation Oncology Center

🇺🇸

Dunmore, Pennsylvania, United States

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Texas Oncology, PA at Texas Cancer Center - Arlington South

🇺🇸

Arlington, Texas, United States

Texas Oncology, PA at Texas Cancer Center - Denton South

🇺🇸

Denton, Texas, United States

Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital

🇺🇸

Fort Worth, Texas, United States

University of Texas Medical Branch

🇺🇸

Galveston, Texas, United States

Longview Cancer Center

🇺🇸

Longview, Texas, United States

Cancer Care Centers of South Texas - Northeast

🇺🇸

San Antonio, Texas, United States

Texas Oncology, PA at Texas Cancer Center - Sherman

🇺🇸

Sherman, Texas, United States

Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land

🇺🇸

Sugar Land, Texas, United States

Tyler Cancer Center

🇺🇸

Tyler, Texas, United States

Texas Oncology, PA - Wichita Falls

🇺🇸

Wichita Falls, Texas, United States

All Saints Cancer Center at Wheaton Franciscan Healthcare

🇺🇸

Racine, Wisconsin, United States

Riverview UW Cancer Center at Riverview Hospital

🇺🇸

Wisconsin Rapids, Wisconsin, United States

British Columbia Cancer Agency - Vancouver Cancer Centre

🇨🇦

Vancouver, British Columbia, Canada

London Regional Cancer Program at London Health Sciences Centre

🇨🇦

London, Ontario, Canada

Princess Margaret Hospital

🇨🇦

Toronto, Ontario, Canada

Rabin Medical Center - Beilinson Campus

🇮🇱

Petach Tikva, Israel

Frederick R. and Betty M. Smith Cancer Treatment Center

🇺🇸

Sparta, New Jersey, United States

Renown Institute for Cancer at Renown Regional Medical Center

🇺🇸

Reno, Nevada, United States

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

🇺🇸

Spartanburg, South Carolina, United States

Arizona Oncology - Tucson

🇺🇸

Tucson, Arizona, United States

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

🇺🇸

Hartford, Connecticut, United States

Elliot Regional Cancer Center at Elliot Hospital

🇺🇸

Manchester, New Hampshire, United States

Rapid City Regional Hospital

🇺🇸

Rapid City, South Dakota, United States

Allan Blair Cancer Centre at Pasqua Hospital

🇨🇦

Regina, Saskatchewan, Canada

Northeastern Ontario Regional Cancer Centre

🇨🇦

Sudbury, Ontario, Canada

Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Boston University Cancer Research Center

🇺🇸

Boston, Massachusetts, United States

Radiological Associates of Sacramento Medical Group, Incorporated

🇺🇸

Sacramento, California, United States

Florida Hospital Cancer Institute at Florida Hospital Orlando

🇺🇸

Orlando, Florida, United States

University of Florida Shands Cancer Center

🇺🇸

Gainesville, Florida, United States

M.D. Anderson Cancer Center at Orlando

🇺🇸

Orlando, Florida, United States

Lucille P. Markey Cancer Center at University of Kentucky

🇺🇸

Lexington, Kentucky, United States

James Graham Brown Cancer Center at University of Louisville

🇺🇸

Louisville, Kentucky, United States

Kansas City Cancer Centers - South

🇺🇸

Kansas City, Missouri, United States

Kansas City Cancer Centers - North

🇺🇸

Kansas City, Missouri, United States

Methodist Estabrook Cancer Center

🇺🇸

Omaha, Nebraska, United States

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center

🇺🇸

Madison, Wisconsin, United States

Veterans Affairs Medical Center - Milwaukee

🇺🇸

Milwaukee, Wisconsin, United States

Forsyth Regional Cancer Center at Forsyth Medical Center

🇺🇸

Winston-Salem, North Carolina, United States

Wake Forest University Comprehensive Cancer Center

🇺🇸

Winston-Salem, North Carolina, United States

Medical College of Wisconsin Cancer Center

🇺🇸

Milwaukee, Wisconsin, United States

Southwest General Health Center

🇺🇸

Middleburg Heights, Ohio, United States

North Coast Cancer Care, Incorporated

🇺🇸

Sandusky, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath